Tonix Pharmaceuticals Holding Corp (TNXP) - News Archive

Tonix Pharmaceuticals Showcases Promising Data for TNX-801 Mpox Vaccine at the World Vaccine Congress Europe 2025In a significant stride towards combating mpox (formerly known as monkeypox) and smallpox, Tonix Pharmaceu...

In a noteworthy presentation at the 7th International Congress on Controversies in Fibromyalgia, Tonix Pharmaceuticals showcased groundbreaking data regarding its innovative therapeutic agent, TNX-102 SL. This sublingua...

Advancements in Migraine Management: Tonix Pharmaceuticals Comprehensive Approach through Technology, Education, and Drug DevelopmentMigraine is a debilitating neurological disorder that affects millions of individuals...

Tonix Pharmaceuticals Holding Corp. Implements Reverse Stock Split Amid Leadership Changes and Mixed Market SignalsOn February 3, 2025, Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceu...

In a strategic move aimed at bolstering its market presence, Tonix Pharmaceuticals Holding Corp has announced the appointment of Gary Ainsworth as Vice President of Market Access. Mr. Ainsworth, with over two decades of...

The pharmaceutical landscape for fibromyalgia (FM) is evolving, as companies pursue innovative treatments to enhance the quality of life for patients. While fibromyalgia has been historically challenging to treat, recen...

In an era defined by rapid advancements in biopharmaceuticals, Tonix Pharmaceuticals is emerging as a pivotal player in addressing urgent public health threats, particularly in the realm of infectious diseases. Recently...

In response to the escalating public health threats posed by the Mpox virus, Tonix Pharmaceuticals has made significant strides in vaccine development. Recent findings, published in the peer-reviewed journal mSphere, un...

Bridging Horizons: Tonix Pharmaceuticals Dual Frontier in Mpox Prevention and Fibromyalgia ReliefIn a significant advancement towards global health security, Tonix Pharmaceuticals has announced a pivotal research collab...

An Extensive for CSIMarket.com In a significant stride for fibromyalgia treatment, Tonix Pharmaceuticals recently announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) f...

The pharmaceutical industry is undergoing a paradigm shift due to advancements in technology, particularly in the realms of artificial intelligence (AI) and machine learning (ML). This transformation is garnering attent...

Tonix Pharmaceuticals Holding Corp has recently marked a significant milestone by participating in a pivotal Endpoints Panel at the Long COVID Workshop and the RECOVER TLC Workshop. These events were convened by the Fou...

Tonix Pharmaceuticals, a trailblazer in the development of novel therapeutics, has recently showcased its innovative approaches to treating debilitating health conditions such as fibromyalgia and cocaine intoxication th...

Tonix Pharmaceuticals Holding Corp has recently presented promising preclinical data for its Mpox vaccine, TNX-801, at the Immunology Symposium at the University of Alberta. This development comes at a time when the com...

Gastroparesis, characterized by delayed gastric emptying, poses significant challenges for patients diagnosed with this condition, especially when it comes to the absorption of orally administered medications. Recent in...

: Tonix Pharmaceuticals has showcased significant advancements in their investigational product TNX-102 SL at the 2024 Military Health System Research Symposium (MHSRS). Presenting data from two posters focusing on the...

In a significant step forward in public health, Tonix Pharmaceuticals and Bilthoven Biologicals have announced a collaborative effort aimed at accelerating the development of Tonix’s Mpox vaccine, TNX-801. This partners...

In an exciting development that signals hope for both patients and clinicians, Tonix Pharmaceuticals has announced the enrollment of the first patient in its Phase 2 study, named CATALYST, assessing TNX-1300 as a potent...

In a crucial development in the fight against mpox, Tonix Pharmaceuticals Holding Corp has issued an update regarding its promising vaccine candidate, TNX-801, which is a single-dose live attenuated virus vaccine design...

Expanding Therapeutic Horizons: Innovations from Tonix Pharmaceuticals in Antibody Development, Migraine Treatment, and Transplant Immunology As the landscape of pharmaceutical science continuously evolves, the pursuit...